Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation titled “Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial,”1 published online April 30, 2015, the byline contained a typographical error. The name should have appeared as Paolo Nuciforo, MD. This article was corrected online. This article was also corrected on May 22, 2015,2 for errors in Figure 2.
Misspelled Author Name. JAMA Oncol. 2015;1(8):1172. doi:10.1001/jamaoncol.2015.4229
Create a personal account or sign in to: